ANGIOVIST 282 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Angiovist 282, and what generic alternatives are available?
Angiovist 282 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in ANGIOVIST 282 is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.
Summary for ANGIOVIST 282
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Patent Applications: | 890 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ANGIOVIST 282 at DailyMed |
US Patents and Regulatory Information for ANGIOVIST 282
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | ANGIOVIST 282 | diatrizoate meglumine | INJECTABLE;INJECTION | 087726-001 | Sep 23, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |